[The concept of innovative drugs rebounded in shock, and offshore protein rose by more than 6% and continued to hit a record high] On September 29th, the concept of innovative drugs rebounded in early trading, and offshore protein rose by more than 6%, continuing to hit a record high. Previously, Jinyao Pharmaceutical had two consecutive boards, Baihua Pharmaceutical, Kanghong Pharmaceutical, Yinuosi, Yifang Biotech, and Betta Pharmaceuticals followed suit. On the news, on September 28, Shanghai Sipurui and Merck jointly announced that the two parties have reached an exclusive global licensing agreement for the investigational preclinical oral KRAS G12D (ON) inhibitor SPR2015. The potential total amount is US$2.13 billion, including an upfront payment of US$400 million, and the remainder will be realized based on development and commercialization milestones.